Furthermore, the association between CD44 and the molecular pathways involved in tumor proliferation and progression (Ras-MAPK and PI3K/Akt pathways), the ability to act as a co-receptor of various growth factors (i.e., HGF, VEGFR-2), and the potential correlation with TMB and MSI status open new research scenarios for the development of innovative strategies in cancer treatment. This evidence concerns the gene AKT1 and cancer.